Compare Torrent Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs AUROBINDO PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA AUROBINDO PHARMA TORRENT PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 53.7 9.8 546.5% View Chart
P/BV x 6.4 1.8 354.6% View Chart
Dividend Yield % 0.8 0.6 137.3%  

Financials

 TORRENT PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
AUROBINDO PHARMA
Mar-19
TORRENT PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,550830 186.7%   
Low Rs1,144527 216.9%   
Sales per share (Unadj.) Rs354.7333.9 106.2%  
Earnings per share (Unadj.) Rs40.140.4 99.3%  
Cash flow per share (Unadj.) Rs64.251.8 124.1%  
Dividends per share (Unadj.) Rs14.002.50 560.0%  
Dividend yield (eoy) %1.00.4 282.2%  
Book value per share (Unadj.) Rs273.1237.1 115.2%  
Shares outstanding (eoy) m169.22585.91 28.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.82.0 186.8%   
Avg P/E ratio x33.616.8 199.9%  
P/CF ratio (eoy) x21.013.1 160.0%  
Price / Book Value ratio x4.92.9 172.3%  
Dividend payout %34.96.2 563.9%   
Avg Mkt Cap Rs m227,897397,569 57.3%   
No. of employees `00014.717.9 82.3%   
Total wages/salary Rs m11,35325,849 43.9%   
Avg. sales/employee Rs Th4,083.010,956.9 37.3%   
Avg. wages/employee Rs Th772.31,447.7 53.3%   
Avg. net profit/employee Rs Th461.31,324.3 34.8%   
INCOME DATA
Net Sales Rs m60,021195,636 30.7%  
Other income Rs m2,9881,553 192.4%   
Total revenues Rs m63,009197,189 32.0%   
Gross profit Rs m13,49339,519 34.1%  
Depreciation Rs m4,0866,680 61.2%   
Interest Rs m3,0852,626 117.5%   
Profit before tax Rs m9,31031,767 29.3%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m2,5297,269 34.8%   
Profit after tax Rs m6,78123,645 28.7%  
Gross profit margin %22.520.2 111.3%  
Effective tax rate %27.222.9 118.7%   
Net profit margin %11.312.1 93.5%  
BALANCE SHEET DATA
Current assets Rs m52,623153,645 34.2%   
Current liabilities Rs m52,022120,429 43.2%   
Net working cap to sales %1.017.0 5.9%  
Current ratio x1.01.3 79.3%  
Inventory Days Days120135 88.5%  
Debtors Days Days7664 119.7%  
Net fixed assets Rs m85,016103,909 81.8%   
Share capital Rs m846586 144.4%   
"Free" reserves Rs m45,376138,322 32.8%   
Net worth Rs m46,222138,908 33.3%   
Long term debt Rs m41,1151,800 2,284.8%   
Total assets Rs m142,432264,544 53.8%  
Interest coverage x4.013.1 30.7%   
Debt to equity ratio x0.90 6,866.3%  
Sales to assets ratio x0.40.7 57.0%   
Return on assets %6.99.9 69.8%  
Return on equity %14.717.0 86.2%  
Return on capital %14.223.8 59.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58097,316 15.0%   
Fx outflow Rs m3,60040,589 8.9%   
Net fx Rs m10,98056,727 19.4%   
CASH FLOW
From Operations Rs m8,94216,220 55.1%  
From Investments Rs m-47,070-28,768 163.6%  
From Financial Activity Rs m34,17419,191 178.1%  
Net Cashflow Rs m-3,6556,656 -54.9%  

Share Holding

Indian Promoters % 71.5 54.1 132.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.0 88.3%  
FIIs % 12.6 27.7 45.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.2 86.3%  
Shareholders   26,511 69,601 38.1%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 19, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS